Compare Sanofi SA (SNY) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.54. The key difference: Sanofi SA pays a 5.5% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Sanofi SA is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| SNY | VCIT | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Fixed Income |
52-Week High | $52.34 | $84.82 |
52-Week Low | $41.33 | $81.45 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCIT trades at $81.71, down 0.28% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts of $0.33-$0.34, reflecting its income-focused strategy. News coverage highlights VCIT's competitive expense ratio of 0.03% and yield advantages over peers like VGIT and IEI, though technical indicators suggest near-term pressure with support clustered around $82.
The outlook balances VCIT's low-cost access to intermediate-term corporate bonds against interest rate sensitivity and economic cycle risks. Current bearish momentum warrants caution, but the fund's structural efficiency and yield appeal position it for income investors seeking diversified credit exposure amid fluctuating fixed-income conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
